Helio Genomics Announces New HelioLiver Access Through Quest
Why This Matters
Business Insider, with 67.7 million monthly visitors, is one of the most influential business and financial news outlets globally. Coverage here puts Helio Genomics directly in front of institutional investors, analysts, and business leaders evaluating the cancer diagnostics market.
Article Summary
Business Insider covers the expanded provider access for HelioLiver beginning April 2026, detailing how healthcare providers with existing Quest accounts can order the blood-based liver cancer test through Quest's infrastructure of approximately 7,700 patient service centers and EHR integration. The article highlights quotes from CEO Dr. Bharat Tewarie, calling it “an important step in widening access to early cancer detection tools,” and Quest’s VP/GM of Oncology Asia Chang, noting that “liquid biopsy may play a meaningful role in aiding earlier cancer detection.”